This is a great result - a common cancer with increasing incidence that often hits people in the prime of life. Great results even with the small sample size, especially when there are no other alternatives. There is more data to be generated here I am sure (on the balance of probability) - as patients fail earlier lines of therapy they have less and less favourable genetic analysis. It is possible that they study its effects on common, unfavourable mutation patterns and make a case for IND study with a view to earlier inclusion. It's important to note DLBCL has many subtypes, and the prognosis can be very different. Something has to be working to get these results.
And the rest of the pipeline looks promising as well.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)